Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives

Area of Science:

• Cardiology
• Pharmacology

Background:

• Thrombolytic therapy is a cornerstone in treating acute myocardial infarction (AMI).
• Several large-scale trials have evaluated its impact on patient survival.
• Comparative studies assessed different thrombolytic agents and their efficacy.

Purpose of the Study:

• To analyze the comparative effectiveness of thrombolytic agents in reducing mortality in AMI.
• To investigate strategies for enhancing coronary reperfusion speed and rate.
• To explore novel pharmacological approaches for improved thrombolysis and prevention of rethrombosis.

Main Methods:

• Review of data from large clinical trials, including GISSI-2, ISIS-3, and GUSTO.
• Comparison of mortality rates between different thrombolytic regimens.
• Evaluation of treatment protocols involving tissue plasminogen activator (t-PA) and heparin.

Main Results:

• The GUSTO trial demonstrated a 14% relative reduction in mortality with accelerated t-PA and intravenous heparin versus streptokinase.
• This finding highlighted the superiority of specific thrombolytic strategies in AMI management.
• Results spurred renewed interest in optimizing reperfusion therapies.

Conclusions:

• Accelerated t-PA combined with heparin offers significant survival benefits in acute myocardial infarction.
• Further research is warranted for developing more effective thrombolytic agents and adjunctive antithrombotic therapies.
• Enhancing coronary reperfusion remains a critical goal in managing AMI.